Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14747277 | 0.87 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL14747292 | 0.87 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL14372181 | 0.87 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL9344087 | 0.87 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL754270 | 0.87 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL14413986 | 0.86 | APLNR (0.40) | TBXAS1CA1CA2APLNRPOLB | |
| SCHEMBL14413962 | 0.86 | APLNR (0.40) | TBXAS1CA1CA2APLNRPOLB | |
| SCHEMBL4619145 | 0.84 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL15721047 | 0.84 | CA1 (0.35) | CA1CA2MMP2MMP3 | |
| SCHEMBL4621789 | 0.84 | CA1 (0.35) | CA1CA2MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20070244184-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2007-10-18 | — | — | US | disclosed |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | SIMON FRASER UNIVERSITY (CA) | 2006-11-02 | — | — | US | disclosed |
| US-20050065139-A1 | Glycosidase inhibitors and methods of synthesizing same | MEDINNOVA PARTNERS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | TBXAS1 2591/4885CA1 148/4885CA2 216/4885 |
| US-20050065139-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | TBXAS1 2205/4885CA1 306/4885CA2 433/4885 |
| US-20070244184-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | ENGASE, GBA3, STS | TBXAS1 3611/4885CA1 244/4885CA2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.